
- amlodipine, a calcium channel blocker (CCB) and
- valsartan, an angiotensin receptor blocker (ARB)
Applications for approval of Exforge in the EU has also been filed earlier this year.
Source: Novartis
« A.P. Pharma Initiates APF530 Phase 3 Clinical Trial | Main | Adventrx Acquires Rights to SDPharma Pipeline »
|
Apr27
|
![]()
Applications for approval of Exforge in the EU has also been filed earlier this year. Source: Novartis |
TrackBack URL for this entry:
« A.P. Pharma Initiates APF530 Phase 3 Clinical Trial | Main | Adventrx Acquires Rights to SDPharma Pipeline »
Use these fast growing business social media sites to promote your business, feature your products, spotlight your business leaders, create links, and drive traffic back to your company site, all for free!
BIZZlogos - Add your logo - free link to your site| View Network Map Network Feed List (OPML) Know More Media Network Feed |
PharmaGazette is a member of the Know More Media network of business related blogs.
Here are some current headlines from some of our business publications:
ProductivityGoal | CallCenterScript |
AdHurl | TheBizofKnowledge |
LandingTheDeal | CustomersAreAlways |
HealthCareVox | BrainBasedBusiness |
TheInsurancePolicy | MarketingBlurb |
Comment Preview